Pradžia › Kraujos vėžys › Oklahoma
Kraujos vėžys klinikiniai tyrimai Oklahoma
8 tyrimai dėl Kraujos vėžys ieško dalyvių vietose Oklahoma.
Miestai Oklahoma
Oficialus tyrimo tekstas (anglų kalba)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0082), Tulsa
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT03486873Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
Renkami dalyviaiStebimasis tyrimasLaukiami sveiki savanoriai
Amžius nuo 40 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT05334069Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Mercy Hospital Oklahoma City, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-09-17 · NCT04242095Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-20 · NCT06001788PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
- OU Health Physicians - Infectious Disease Clinic, Oklahoma City
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-04 · NCT06665100A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-07-06 · NCT01351545A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- University of Oklahoma Health Sciences Center, Oklahoma City
Renkami dalyviai3 fazė
Amžius nuo 2 iki 18 · Visoms lytims · Atnaujinta 2026-05-05 · NCT05711667A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-03-13 · NCT05735184Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.